Patents by Inventor Fukushi Hirayama

Fukushi Hirayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7361658
    Abstract: 2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: April 22, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Keizo Sugasawa, Yuji Koga, Kazuyoshi Obitsu, Takao Okuda, Koichiro Harada, Hideki Kubota, Fukushi Hirayama, Masaki Abe, Ken-ichi Suzuki
  • Patent number: 7307074
    Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4?-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: December 11, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe
  • Publication number: 20060194844
    Abstract: 2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided.
    Type: Application
    Filed: July 15, 2004
    Publication date: August 31, 2006
    Inventors: Keizo Sugasawa, Yuji Koga, Kazuyoshi Obitsu, Takao Okuda, Koichiro Harada, Hideki Kubota, Fukushi Hirayama, Masaki Abe, Ken-ichi Suzuki
  • Publication number: 20060148806
    Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
    Type: Application
    Filed: July 22, 2004
    Publication date: July 6, 2006
    Inventors: Susumu Watanuki, Yuji Koga, Hiroyuki Moritomo, Issei Tsukamoto, Daisuke Kaga, Takao Okuda, Fukushi Hirayama, Yumiko Moritani, Jun Takasaki
  • Publication number: 20050153977
    Abstract: A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.
    Type: Application
    Filed: January 15, 2003
    Publication date: July 14, 2005
    Inventors: Keizo Sugasawa, Susumu Watanuki, Yuji Koga, Hiroshi Nagata, Kazuyoshi Obitsu, Ryutaro Wakayama, Fukushi Hirayama, Ken-ichi Suzuki
  • Publication number: 20040077555
    Abstract: There are provided compounds having an anticoagulant action on the basis of inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism. Effective ingredients are the compounds such as 4′-bromo-2′-[(5-chloro-2-pyridyl)carbamoyl]-6′-&bgr;-D-galactopyranosyloxy-1-isopropylpiperidine-4-carboxanilide, 2′-(2-acetamido-2-deoxy-&bgr;-D-glucopyranosyloxy)-4′-bromo-6′-[(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide, etc. or salts thereof.
    Type: Application
    Filed: September 10, 2003
    Publication date: April 22, 2004
    Inventors: Tsukasa Ishihara, Fukushi Hirayama, Keizo Sugasawa, Yuji Koga, Takeshi Kadokura, Takeshi Shigenaga
  • Publication number: 20040068109
    Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4′-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.
    Type: Application
    Filed: September 8, 2003
    Publication date: April 8, 2004
    Applicant: YAMANOUCHI PHARMACEUTICAL CO. LTD.
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe
  • Patent number: 6642224
    Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-METHYL-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4′-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: November 4, 2003
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe
  • Publication number: 20030195193
    Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4′methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.
    Type: Application
    Filed: October 2, 2002
    Publication date: October 16, 2003
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Haehiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi shigenaga, Souichirou Kawazoe
  • Patent number: 6333320
    Abstract: Hexahydro-1,4-diazepine derivatives represented by general formula (I); pharmaceutically acceptable salts thereof; and drugs containing the same as the active ingredient, such as activated blood coagulation factor X inhibitor, wherein A: phenylene, pyridylene, or the like; B: a 5- or 6-membered aryl or heteroaryl ring; X: —CO—, —CONH—, —CSNH—, —SO2—, —SO2NH—, or the like; Y: a bond or alkylene; R1: hydrogen, alkyl, —Y—(hetero) aryl, or the like; R2: hydrogen, alkoxy, —COOH, or the like; R3: amidino or a group capable of being converted into amidino; and R4, R5: each independently hydrogen or lower alkyl.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: December 25, 2001
    Assignee: Yamanouchi Pharmaceutical Co.
    Inventors: Hiroyuki Koshio, Fukushi Hirayama, Tsukasa Ishihara, Masashi Funatsu, Tomihisa Kawasaki, Yuzo Matsumoto
  • Patent number: 5869501
    Abstract: An amidinonaphthyl derivative represented by the following general formula (I) which has coagulation factor X inhibiting action and is useful as an anti-thrombus agent and the like, a salt thereof, an intermediate thereof and a pharmaceutical composition which comprises the amidinonaphthyl derivative. An amidinonaphthyl derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. ##STR1## (symbols in the formula have the following meanings; R.sup.1 : a hydrogen atom or a group represented by the formula --A--W--R.sup.4,A: a group represented by the formula ##STR2## a group represented by the formula ##STR3## or a group represented by the formula --SO.sub.2 --, X: an oxygen atom or a sulfur atom, W: a single bond or a group represented by the formula --NR.sup.5 --, R.sup.4 : a hydroxyl group, a lower alkoxy group, etc., R.sup.5 : a hydrogen atom, a carbamoyl group, a lower alkoxycarbonyl group, etc., R.sup.2 : a lower alkyl group, R.sup.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: February 9, 1999
    Assignee: Yamanouchi Pharmaceutical Co. Ltd
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Yuzo Matsumoto, Tomihisa Kawasaki, Seiji Kaku, Isao Yanagisawa
  • Patent number: 5159069
    Abstract: Sulfated tannins or salts thereof are herein disclosed. These compounds can be prepared by a method which comprises reacting tannin with a sulfonating agent under a basic condition. These compounds show antiviral activity and reverse transcriptase inhibitor, effects and can be used to treat patients infected with a variety of virus such as AIDS virus, herpesvirus, influenza virus or rhinovirus.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: October 27, 1992
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., NipponFlour Mills Co., Ltd.
    Inventors: Fukushi Hirayama, Keijiro Uchino, Masaya Iwamoto, Akira Fukuchi, Masashi Hiramoto, Hirokazu Yamamoto, Naoki Yamamoto, Hideki Nakashima, Shigenobu Kadota, Hiroshi Ogawara